<?xml version="1.0" encoding="UTF-8"?>
<p id="Par31">Randomized controlled trials have demonstrated that early initiation of ART during TB therapy improved survival of TB-HIV co-infected patients by 56% [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, initiating ART early during TB treatment (within 2–4 weeks) increased AIDS-free survival by 34–68% among patients with advanced HIV disease [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR17">17</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>]. In spite of TB-HIV integration being incorporated into international and South African guidelines, mortality rates in 2015 for TB-HIV co-infected patients in South Africa was 133 per 100,000 population, which is more than three times higher than mortality in HIV-negative TB patients, who had mortality rates of 46 per 100,000 population [
 <xref ref-type="bibr" rid="CR2">2</xref>].
</p>
